Institute of Pneumology at the University Witten/Herdecke, Clinic for Pneumology and Allergology, Center of Sleep Medicine and Respiratory Care, Bethanien Hospital, Solingen.
Institute of Pneumology at the University Witten/Herdecke, Clinic for Pneumology and Allergology, Center of Sleep Medicine and Respiratory Care, Bethanien Hospital, Solingen.
Chest. 2012 Aug;142(2):440-447. doi: 10.1378/chest.11-2089.
The coexistence of obstructive sleep apnea (OSA) and central sleep apnea (CSA) and Cheyne-Stokes respiration (CSR) is common in patients with heart failure (HF). While CPAP improves CSA/CSR by about 50%, maximal suppression is crucial in improving clinical outcomes. Auto-servoventilation (ASV) effectively suppresses CSA/CSR in HF, but few trials have been performed in patients with coexisting OSA and CSA/CSR. Our objective was to evaluate a randomized, controlled trial to compare the efficacy of ASV and CPAP in reducing breathing disturbances and improving cardiac parameters in patients with HF and coexisting sleep-disordered breathing.
Both modes were delivered using the BiPAP autoSV (Philips Respironics) over a 12-month period. Seventy patients (63 men, 66.3 ± 9.1 y, BMI 31.3 ± 6.0 kg/m(2)) had coexisting OSA and CSA/CSR, arterial hypertension, coronary heart disease, or cardiomyopathy and clinical signs of heart failure New York Heart Association classes II-III. Polysomnography, brain natriuretic peptide (BNP), spiroergometry, and echocardiography were performed at baseline and after 3 and 12 months of treatment.
Both modes of therapy significantly improved respiratory disturbances, oxygen desaturations, and arousals over the study period. ASV reduced the central apnea hypopnea index (baseline CPAP, 21.8 ± 11.7; ASV, 23.1 ± 13.2; 12 months CPAP, 10.7 ± 8.7; ASV, 6.1 ± 7.8, P < .05) and BNP levels (baseline CPAP, 686.7 ± 978.7 ng/mL; ASV, 537.3 ± 891.8; 12 months CPAP, 847.3 ± 1848.1; ASV, 230.4 ± 297.4; P < .05) significantly more effectively as compared with CPAP. There were no relevant differences in exercise performance and echocardiographic parameters between the groups.
ASV improved CSA/CSR and BNP over a 12-month period more effectively than CPAP.
阻塞性睡眠呼吸暂停(OSA)和中枢性睡眠呼吸暂停(CSA)及 Cheyne-Stokes 呼吸(CSR)共存于心力衰竭(HF)患者中很常见。尽管 CPAP 可使 CSA/CSR 降低约 50%,但最大程度的抑制对于改善临床结局至关重要。自动伺服通气(ASV)可有效抑制 HF 中的 CSA/CSR,但很少有试验在合并 OSA 和 CSA/CSR 的患者中进行。我们的目的是评估一项随机对照试验,比较 ASV 和 CPAP 降低合并睡眠呼吸障碍的 HF 患者呼吸紊乱和改善心功能参数的疗效。
两种模式均使用 BiPAP autoSV(飞利浦伟康)在 12 个月内进行治疗。70 例患者(63 名男性,66.3±9.1 岁,BMI 31.3±6.0 kg/m²)合并 OSA 和 CSA/CSR、动脉高血压、冠心病或心肌病以及纽约心功能协会(NYHA)心功能 II-III 级的心力衰竭临床体征。治疗前和治疗后 3 个月和 12 个月时进行了多导睡眠图、脑钠肽(BNP)、测功计和超声心动图检查。
两种治疗模式在整个研究期间均显著改善了呼吸紊乱、氧饱和度下降和觉醒。与 CPAP 相比,ASV 更显著地降低了中枢性呼吸暂停低通气指数(治疗前 CPAP,21.8±11.7;ASV,23.1±13.2;治疗 12 个月 CPAP,10.7±8.7;ASV,6.1±7.8,P<.05)和 BNP 水平(治疗前 CPAP,686.7±978.7 ng/mL;ASV,537.3±891.8;治疗 12 个月 CPAP,847.3±1848.1;ASV,230.4±297.4;P<.05)。两组在运动表现和超声心动图参数方面无显著差异。
与 CPAP 相比,ASV 在 12 个月内更有效地改善了 CSA/CSR 和 BNP。